ES2077643T3 - Compuestos antivirales. - Google Patents

Compuestos antivirales.

Info

Publication number
ES2077643T3
ES2077643T3 ES90303818T ES90303818T ES2077643T3 ES 2077643 T3 ES2077643 T3 ES 2077643T3 ES 90303818 T ES90303818 T ES 90303818T ES 90303818 T ES90303818 T ES 90303818T ES 2077643 T3 ES2077643 T3 ES 2077643T3
Authority
ES
Spain
Prior art keywords
formula
substituted
residue
nucleotide base
antiviral compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90303818T
Other languages
English (en)
Inventor
Richard Thomas Walker
Albert Stanley Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
British Technology Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898908355A external-priority patent/GB8908355D0/en
Application filed by British Technology Group Ltd filed Critical British Technology Group Ltd
Application granted granted Critical
Publication of ES2077643T3 publication Critical patent/ES2077643T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

COMPUESTOS DE LA FORMULA I O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE EL, EN CUYA FORMULA R1 REPRESENTA A UN GRUPO ALIFATICO HIDROCARBILO; AR REPRESENTA A UN NUCLEO AROMATICO SUSTITUIDO O NO SUSTITUIDO; X REPRESENTA -SO2- O -CO-, Y R2 Y R3, QUE PUEDEN SER MOLECULAS IGUALES O DISTINTAS DE FORMULA (A), (B), (C), (D), (E), (F), (G), (H), O (I): EN DONDE B REPRESENTA EL RESIDUO DE UNA BASE NUCLEOTIDA DE FORMULA (A), (G), (C), (H) O (T): SIMEPRE QUE CUANDO R2 Y R3 REPRESENTAN A UNA MOLECULA NO SUSTITUIDA DE FORMULA (A), B REPRESENTA EL RESIDUO DE UNA BASE NUCLEOTIDA CUYA FORMULA ES (A), (G), (C) O (H) CON VALOR DE ACTIVIDAD ANTIVIRICA.
ES90303818T 1989-04-13 1990-04-10 Compuestos antivirales. Expired - Lifetime ES2077643T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898908355A GB8908355D0 (en) 1988-04-18 1989-04-13 Output apparatus antiviral compounds

Publications (1)

Publication Number Publication Date
ES2077643T3 true ES2077643T3 (es) 1995-12-01

Family

ID=10654960

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90303818T Expired - Lifetime ES2077643T3 (es) 1989-04-13 1990-04-10 Compuestos antivirales.

Country Status (16)

Country Link
EP (1) EP0392791B1 (es)
JP (1) JPH03505880A (es)
KR (1) KR920700217A (es)
CN (1) CN1046531A (es)
AT (1) ATE125817T1 (es)
AU (1) AU5407890A (es)
CA (1) CA2028151A1 (es)
DE (1) DE69021242T2 (es)
ES (1) ES2077643T3 (es)
FI (1) FI906113A0 (es)
GB (1) GB2230266B (es)
NZ (1) NZ233197A (es)
OA (1) OA09553A (es)
PT (1) PT93743A (es)
WO (1) WO1990012023A1 (es)
ZA (1) ZA902784B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
US5728575A (en) 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US6228860B1 (en) 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US6369066B1 (en) 1990-11-13 2002-04-09 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
AU1254892A (en) * 1990-12-18 1992-07-22 Sloan-Kettering Institute For Cancer Research Novel synthesis of 2'-"up" fluorinated 2''-deoxy-arabinofuranosylpurines
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
FR2685331A1 (fr) * 1991-12-12 1993-06-25 Centre Nat Rech Scient Phosphotriesters de la ddu, leur preparation et leur application en therapeutique.
CA2129986C (en) * 1992-02-13 2003-12-09 Albert Reto Schwendener Amphiphile nucleosidphosphatanaloga
US6005107A (en) * 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
GB9226879D0 (en) * 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
ES2129893T3 (es) * 1994-07-15 1999-06-16 Biosearch Italia Spa Dinucleosido-5',5'-pirofosfatos.
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
PT831852E (pt) 1995-06-07 2007-02-28 Uab Research Foundation Nucleósidos com actividade anti-vírus da hepatite b
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
AU6551800A (en) * 1999-08-17 2001-03-13 Adani, Alexander Dinucleoside 5',5'-tetraphosphates as inhibitors of viral reverse transcriptasesand viruses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA931561A (en) * 1969-03-10 1973-08-07 Syntex Corporation Nucleoside phosphonates, phosphonic acids, phosphonic acid salts, and process for producing same
CA1330794C (en) * 1987-03-27 1994-07-19 Phillip Frost Anti-viral compounds, dosage forms and methods

Also Published As

Publication number Publication date
FI906113A7 (fi) 1990-12-12
DE69021242D1 (de) 1995-09-07
EP0392791A1 (en) 1990-10-17
JPH03505880A (ja) 1991-12-19
DE69021242T2 (de) 1996-01-11
GB2230266A (en) 1990-10-17
GB2230266B (en) 1992-08-12
ZA902784B (en) 1991-12-24
EP0392791B1 (en) 1995-08-02
ATE125817T1 (de) 1995-08-15
CA2028151A1 (en) 1990-10-14
WO1990012023A1 (en) 1990-10-18
FI906113A0 (fi) 1990-12-12
PT93743A (pt) 1990-11-20
GB9008105D0 (en) 1990-06-06
OA09553A (en) 1993-01-31
NZ233197A (en) 1991-11-26
AU5407890A (en) 1990-11-05
KR920700217A (ko) 1992-02-19
CN1046531A (zh) 1990-10-31

Similar Documents

Publication Publication Date Title
ES2077643T3 (es) Compuestos antivirales.
AR248138A1 (es) Un procedimiento de preparacion de acilamino-2-tiazoles.
DE3880047D1 (de) Zusammensetzung eines zusatzes.
FI944217L (fi) Substituoidut pipekoliinihappojohdannaiset HIV-proteaasin estäjinä
NO882472D0 (no) Fremgangsmaate for fremstilling av peptidborsyreinhibitorer for trypsinlignende proteaser.
ES2028048T3 (es) Composiciones cataliticas y procedimiento de copolimerizacion de olefinas/monoxido de carbono.
DE69007337D1 (de) Gaserzeugende Zusammensetzungen, die Salze der 5-Nitro-Barbitursäure oder Salze der Nitro-Orotsäure oder 5-Nitro-Uracil enthalten.
NO855134L (no) 6,7-disubstituerte 1-syklopropyl-1,4-dihydro-4-okso-1,8-naftyridin-3-karboksylsyrer.
DK0389035T3 (da) Farmaceutisk præparat der indeholder en farmaceutisk egnet bærer og forbindelsen med strukturen (7alfa,17alfa)-17-hydroxy-7-methyl-19-nor-17-pregn-5-(10)-en-20-yn-3-on
DE69003906D1 (de) Triacetin enthaltende, langwirkende injizierbare Zusammensetzungen.
ATE165827T1 (de) Herstellung von n-acetylneuraminsäure-derivaten
NO308607B1 (no) Kjemisk forbindelse, et farmasøytisk preparat inneholdende denne, samt anvendelse av forbindelsen til fremstilling av en blodplateaggregeringsinhibiotor og fremstilling av et farmasøytisk preparat til behandling eller forebygging av trombotiske
ES8801211A1 (es) Un procedimiento para preparar derivados de quinolona
DK407882A (da) 2beta-substituerede 2alfa-methyl-5(r)penam-3alfa-carboxylsyre-1,1-dioxider og mellemprodukter herfor og deres fremstilling
ES2029845T3 (es) Procedimiento para preparar derivados de 1,5-benzotiazepina
DE69012882D1 (de) Herstellung von Stickstoffzusammensetzungen.
ES2059767T3 (es) Derivado de 1,4-dihidropiridina.
ES2043072T3 (es) Procedimiento para la diacilacion de compuestos que comprenden dos nucleos aromaticos.
DE3878506D1 (de) Hochtemperaturentschweflung von synthesegas.
ES2097435T3 (es) Derivados de 2,16-bispiperidinilandrostano monocuaternarios.
DE68905075D1 (de) Herstellung von tris(2-zyanaethyl)amin.
DE3861556D1 (de) Verhinderung von ablagerungen.
ES2032838T3 (es) Un procedimiento para preparar derivados tetrahidropirido (1,2-a)indol.
ATE104986T1 (de) Aminsalze von 1,4,2-oxazaphospholidin-2-alkoxy-2oxid-4-essigs|uren.
DE3851323D1 (de) Eutektische Zusammensetzung von zwei Nitrazapentanderivaten.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 392791

Country of ref document: ES